Emmanuel Raffoux
Overview
Explore the profile of Emmanuel Raffoux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
5213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Urbino I, Lengline E, Rabian F, Cerrano M, Kim R, Chevillon F, et al.
Blood Adv
. 2024 Mar;
8(10):2405-2409.
PMID: 38507689
No abstract available.
12.
Chalandon Y, Rousselot P, Chevret S, Cayuela J, Kim R, Huguet F, et al.
Blood
. 2024 Mar;
143(23):2363-2372.
PMID: 38452207
We previously demonstrated that a reduced-intensity chemotherapy schedule can safely replace hyper-CVAD (cyclophosphamide-vincristine-doxorubicin [Adriamycin]-dexamethasone) cycle 1 when combined with imatinib in adults with Philadelphia-positive acute lymphoblastic leukemia. In the present...
13.
Rea D, Fodil S, Lengline E, Raffoux E, Cayuela J
Curr Hematol Malig Rep
. 2024 Feb;
19(3):104-110.
PMID: 38393431
Purpose Of Review: The discovery that patients suffering from chronic myeloid leukemia who obtain deep and long-lasting molecular responses upon treatment with tyrosine kinase inhibitors may maintain their disease silent...
14.
Freiman L, Larcher L, Tueur G, Vasquez N, Da Costa M, Duchmann M, et al.
Leukemia
. 2024 Feb;
38(4):908-911.
PMID: 38378842
No abstract available.
15.
Guerra M, Pasquer H, Daltro de Oliveira R, Soret-Dulphy J, Maslah N, Zhao L, et al.
Am J Hematol
. 2024 Jan;
99(4):741-744.
PMID: 38279562
Comparative clinical characteristics, molecular landscape and prognosis scoring for primary (PMF) and secondary myelofibrosis (SMF).
16.
Gabellier L, Peterlin P, Thepot S, Hicheri Y, Paul F, Gallego-Hernanz M, et al.
Ann Hematol
. 2024 Jan;
103(3):759-769.
PMID: 38273140
Very few data are available about hypomethylating agent (HMA) efficiency in core binding factor acute myeloid leukemias (CBF-AML). Our main objective was to evaluate the efficacy and safety of HMA...
17.
Urbino I, Lengline E, Valade S, Cerrano M, Sebert M, Raffoux E, et al.
Crit Care
. 2024 Jan;
28(1):14.
PMID: 38183144
No abstract available.
18.
Pasquer H, Daltro de Oliveira R, Vasseur L, Soret-Dulphy J, Maslah N, Zhao L, et al.
Leukemia
. 2023 Dec;
38(2):326-339.
PMID: 38148396
Current recommended risk scores to predict thrombotic events associated with myeloproliferative neoplasms (MPN) do not discriminate between arterial and venous thrombosis despite their different physiopathology. To define novel stratification systems,...
19.
Kim R, Bergugnat H, Pastoret C, Pasquier F, Raffoux E, Larcher L, et al.
Blood
. 2023 Aug;
142(21):1806-1817.
PMID: 37595275
KMT2A-rearranged (KMT2A-r) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is widely recognized as a high-risk leukemia in both children and adults. However, there is a paucity of data on adults treated...
20.
Elessa D, Zhao L, Daltro de Oliveira R, Maslah N, Soret-Dulphy J, Verger E, et al.
Leukemia
. 2023 Jul;
37(8):1741-1744.
PMID: 37433887
No abstract available.